IFN-γ is FDA-approved for the treatment Chronic Granulomatous Disease patients at risk of invasive fungal and other infections in combination with antifungal therapy and Granulocyte-macrophage colony-stimulating factor (GM-CSF) (347). The gene discussed is CSF2; the disease is chronic granulomatous disease.